Cochrane · systematic review · CD007811

Sulpiride versus placebo for schizophrenia

Wang, J, Sampson, S · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library

SchizophreniaAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
2
No studies
5
Included studies
NR
No studies 5 · 71.4%Ungraded 0 · 0%Very low 2 · 28.6%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

SULPIRIDE compared to PLACEBO for schizophrenia

Population: people with schizophrenia
7 questions
OutcomeEffectEvidenceStatus / GRADE
Global state: clinically significant response in global state ‐ by long term ‐ not measured
SULPIRIDE vs PLACEBO
no estimate extractedNRNo studies
Mental state: average score for positive symptoms (skewed) ‐ by short term Manchester Scale, positive subset endpoint
SULPIRIDE vs PLACEBO
no estimate extracted1 study · 18 participantsVery low
Downgraded: risk of bias, imprecision
Mental state: average score for negative symptoms ‐ by short term Manchester Scale, negative subset endpoint. Scale from: 0 to 20.
SULPIRIDE vs PLACEBO
no estimate extracted1 study · 18 participantsVery low
Downgraded: risk of bias, imprecision
Mental state: average score for depressive and anxious symptoms ‐ by medium term ‐ not measured
SULPIRIDE vs PLACEBO
no estimate extractedNRNo studies
Quality of life: average score ‐ by long term ‐ not measured
SULPIRIDE vs PLACEBO
no estimate extractedNRNo studies
Severe adverse effects ‐ medium term ‐ not reported
SULPIRIDE vs PLACEBO
no estimate extractedNRNo studies
Safety assessments ‐ medium term ‐ not measured
SULPIRIDE vs PLACEBO
no estimate extractedNRNo studies